Related Experiment Video
Updated: Sep 24, 2026

Mouse- and Human-derived Primary Gastric Epithelial Monolayer Culture for the Study of Regeneration
Published on: May 7, 2018
Effects of misoprostol on gastric pepsin secretion and human mucosal cell loss in man
1Department of Medicine, State University of New York, Brooklyn 11203.
Abstract:
The present study determined the effect of an orally administered prostaglandin E1 analogue, misoprostol (200, 400 and 800 micrograms) on pepsin secretion and the recovery of DNA (mucosal cell loss) in human gastric juice. Effects on basal pepsin secretion, and pepsin and DNA following secretory stimulation with pentagastrin, were measured over a period of 150 minutes. At the higher dosages, compared with placebo, misoprostol significantly reduced pepsin output and concentration. Gastric juice DNA was also significantly increased during the initial 45 minutes of the study. Considering the dose-response effects observed, the misoprostol action most likely represents a direct effect on the chief cell. The effect on DNA could be the result of multiple factors, including stimulation of synthesis and/or cell migration. The antiulcer effect of prostaglandins is known to consist of both an acid antisecretory and mucosal protective component. Inhibition of pepsin and stimulation of cell turnover may also play a role in this effect.
Related Concept Videos
Pathophysiology of Peptic Ulcer Disease: Injurious Factors
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds to M3...
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Peptic Ulcer Disease II: Pathophysiology
